Mineralys Therapeutics Inc. has announced the successful achievement of statistical significance in its Explore-CKD Phase 2 trial, which focused on reducing systolic blood pressure and urinary albumin-to-creatinine ratio (UACR) while demonstrating a favorable safety profile. The company also continues its Explore-OSA Phase 2 trial involving participants with obstructive sleep apnea (OSA) and hypertension, with topline results anticipated in the first half of 2026. Additionally, Mineralys has presented positive results from its Launch-HTN and Advance-HTN pivotal trials at scientific meetings and published them in JAMA and NEJM. The company is preparing for a pre-NDA meeting with the FDA, scheduled for the fourth quarter of 2025, as part of its strategy to advance the development of lorundrostat for treating hypertension and related conditions.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。